Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth

Core Viewpoint - Alnylam Pharmaceuticals, Inc. is considered a strong healthcare stock for 2026, with RBC Capital maintaining an Outperform rating but lowering the price target to $465 from $500 [1]. Group 1: Analyst Views - Alnylam Pharmaceuticals aims for a revenue target of $5.1 billion, surpassing the consensus estimate of $4.7 billion, with a long-term goal of a 25% compound annual growth rate through 2030, leading to projected revenue of $11.2 billion [2]. - Cantor Fitzgerald has a Neutral rating on Alnylam Pharmaceuticals, citing a slowdown in Amvuttra cardiomyopathy sales in November, although sales rebounded in December. The firm anticipates a mid-single-digit decline in Amvuttra's net price by 2026, influencing their cautious outlook [3]. Group 2: Company Overview - Alnylam Pharmaceuticals specializes in developing innovative medicines using RNA interference (RNAi) technology to target and silence disease-causing genes, focusing on treatments for rare and common genetic, metabolic, cardiovascular, and neurological diseases [4].